Van Hauwermeiren Timothy

SEC source: 0001816206-26-000005 · form4-06292026_080640.xml · derivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2036-06-24

F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

SEC source: 0001816206-26-000003 · wk-form4_1780692290.xml · derivative · entry 2

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,226

Underlying: Common Stock · 19,226 shares

Expires 2036-06-03

F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

SEC source: 0001816206-26-000003 · wk-form4_1780692290.xml · nonDerivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,040

F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

F2 · balance_after: Includes 17,040 unvested RSUs.

SEC source: 0001816206-25-000007 · wk-form4_1762478196.xml · derivative · entry 2

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,897

Underlying: Common Stock · 31,897 shares

Expires 2034-11-04

F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on November 4, 2026, and an additional 1/48 of the shares subject to the option vest each month thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date

SEC source: 0001816206-25-000007 · wk-form4_1762478196.xml · nonDerivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,632

F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. The RSU award vests over a four-year period, with 1/4th of the shares vesting on each anniversary of the grant date (or, for the last tranche that otherwise would vest on the fourth anniversary of the grant date, on such anniversary or, if earlier, on the day prior to the Company's next annual meeting of stockholders occurring after the third anniversary of the grant date), provided that he remains a non-employee director through the applicable vesting date.

F2 · balance_after: Includes 10,632 unvested RSUs.

SEC source: 0001415889-25-018523 · form4-06302025_050614.xml · derivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,916

Underlying: Common Stock · 22,916 shares

Expires 2035-06-25

F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date.

SEC source: 0000950170-25-071755 · ownership.xml · derivative · entry 2

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,346 shares

Expires 2025-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.

SEC source: 0000950170-25-071755 · ownership.xml · nonDerivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-019380 · form4-07082024_100700.xml · derivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2034-07-04

F1 · derivative.exercise_date: The shares subject to the option shall vest and become exercisable in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service.

SEC source: 0000950170-24-073257 · ownership.xml · derivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,200

Underlying: Common Stock · 24,200 shares

Expires 2034-06-11

SEC source: 0001415889-24-005541 · form4-02272024_100250.xml · derivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 48,628 shares

Expires 2033-10-31

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

SEC source: 0001628280-23-035965 · wk-form4_1698869329.xml · derivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,628

Underlying: Common Stock · 48,628 shares

Expires 2033-10-31

F1 · derivative.exercise_date: The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant.

SEC source: 0001209191-23-037595 · doc4.xml · derivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,383

Underlying: Common Stock · 22,383 shares

Expires 2033-06-13

SEC source: 0001209191-22-036143 · doc4.xml · derivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,538

Underlying: Common Stock · 17,538 shares

Expires 2032-06-09

F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-21-025140 · doc4.xml · derivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,608 shares

Expires 2031-06-17

F1 · derivative.exercise_date: This stock option shall vest and become exercisable in full upon the earlier to occur of (a) June 17, 2022 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-20-020446 · doc4.xml · derivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,608 shares

Expires 2030-07-23

F1 · derivative.exercise_date: This stock option shall vest over 3 years, with 1/3 vesting on July 23, 2021 and thereafter in equal monthly installments over the next 24 months subject to the Reporting Person's continued service to the Issuer.

SEC source: 0000899243-20-028897 · doc4a.xml · derivative · entry 1

Van Hauwermeiren Timothy · CIK 0001816206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,608 shares

Expires 2030-07-23

F1 · derivative.exercise_date: This amendment is being filed solely for the purpose of correcting the vesting schedule, as follows: this stock option shall vest on the earlier of (i) the first anniversary of the grant date or (ii) the Company's next annual meeting of stockholders following the grant date, subject to continued service through the applicable vesting date.